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Ina Gylys-Colwell, MS,3 Olivier Humblet, ScD,5 Huong Q. Nguyen, PhD, RN,6
Rachel M. Thomas, MPH,3 and Vincent S. Fan, MD, MPH3,7
Abstract
Background: Remote inhaler monitoring is an emerging technology that enables the healthcare team to monitor
the time and location of a patient’s inhaler use. We assessed the feasibility of remote inhaler monitoring for
chronic obstructive pulmonary disease (COPD) patients and the pattern of albuterol inhaler use associated with
COPD exacerbations.
Methods: Thirty-five participants with COPD used an electronic inhaler sensor for 12 weeks which recorded the
date and time of each albuterol actuation. Self-reported COPD exacerbations and healthcare utilization were
assessed monthly. We used generalized estimating equations with a logit link to compare the odds of an
exacerbation day to a nonexacerbation day by the frequency of daily albuterol use.
Results: Average daily albuterol use on nonexacerbation days varied greatly between patients, ranging from 1.5 to
17.5 puffs. There were 48 exacerbation events observed in 29 participants during the study period, of which 16 were
moderate-to-severe exacerbations. During the moderate-to-severe exacerbation days, the median value in average
daily albuterol use increased by 14.1% (interquartile range: 2.7%–56.9%) compared to average nonexacerbation
days. A 100% increase in inhaler use was associated with increased odds of a moderate-to severe exacerbation (odds
ratio 1.54; 95% CI: 1.21–1.97). Approximately 74% of participants reported satisfaction with the sensor.
Conclusions: The electronic inhaler sensor was well received in older patients with COPD over a 12-week
period. Increased albuterol use captured by the device was associated with self-reported episodes of moderate-
to-severe exacerbations.
Keywords: pulmonary disease, chronic obstructive, telemedicine, adrenergic beta-agonists, metered dose inhaler,
signs and symptoms, respiratory
Introduction
Remote monitoring of inhaler use is a recently de-veloped technology that captures the time of inhaler
actuations using a device that attaches to the inhaler. There
are several Food and Drug Administration (FDA) cleared
sensor devices, which attach to the pressurized meter-dose
inhalers (MDIs) and additional models that fit to different
types of inhalers.(1) Electronic sensors were shown to accu-
rately capture inhaler actuations over a 6-month period(2,3)
and their use was demonstrated to improve medication ad-
herence(4,5) and symptom control(6,7) in asthma patients.
However, benefit and acceptability of these devices were
tested mainly in younger asthma patients. There is a paucity
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of data of remote inhaler monitoring use in chronic ob-
structive pulmonary disease (COPD) patients, who tend to be
older and have multiple comorbidities. Increases in short-
acting beta-agonist (SABA) inhaler use often accompany
worsening breathing symptoms characteristic of COPD ex-
acerbations.(8) As such, inhaler sensors may be used to detect
COPD exacerbations before patients seeking healthcare.
Therefore, we assessed the feasibility of using a remote in-
haler sensor in COPD patients and ascertained if the pattern
of albuterol inhaler use was associated with COPD exacer-
bations.
Materials and Methods
Study design and participants
We conducted a 12-week pilot study in Veterans with
COPD from December 2011 to January 2014. Inclusion
criteria included: (1) veterans receiving care at VA Puget
Sound Healthcare System in Seattle and Tacoma, Wa-
shington, (2) clinical diagnosis of COPD, (3) currently using
an albuterol inhaler, (4) over 40 years of age, (5) former
smoker with >10 pack year history, (6) residence in King or
Pierce Counties in Washington State (due to availability of
air pollution monitors needed for a secondary aim for the
study), (7) post bronchodilator forced expiratory volume in
1 second (FEV1)% predicted £80%, and (8) no exacerba-
tions in the 4 weeks before enrollment.
Exclusion criteria were: (1) diagnosis of asthma and (2)
Modified Medical Research Council (MMRC) dyspnea
scale score of 4 (too breathless to leave the house or
breathless when dressing). Housebound patients with very
severe COPD (MMRC scale of 4) were excluded due to a
secondary aim of the study that evaluated the relationship of
COPD exacerbation with air pollution and physical activity,
which is not included in this analysis. This study was ap-
proved by the VA Puget Sound Healthcare Center IRB (ID:
00408). All participants provided informed consent.
At baseline, participants completed questionnaires re-
garding medical history, respiratory symptoms, physical
activity, and health related quality of life. In the medical
history questionnaire, participants were asked if they had a
nebulizer device, whether it was used for albuterol or ipra-
tropium, and how often they used it. Participants completed
the University of California San Diego (UCSD) Shortness of
Breath Questionnaire (SOBQ).(9) The 24-item questionnaire
assesses dyspnea with various activities of daily living
(scores range from 0 = best to 120 = worse), with a minimal
clinically important difference of five points.(10) The mean
SOBQ score among a previous cohort of COPD patients was
63.4 (standard deviation: 18.5).(11) COPD exacerbations and
breathing symptoms were ascertained during monthly in-
terviews as stated below. All participants were given a daily
diary to record respiratory symptoms, treatment of exacer-
bations, and the number of daily puffs during the 3-month
follow-up period.
Inhaler sensor
The study contracted with Propeller Health (Madison,
WI) to provide participants the FDA-cleared portable
electronic inhaler sensor to monitor participants’ albuterol
use. The sensor and the Propeller Health System are de-
scribed elsewhere.(6) With the exception of the first three
participants who used an earlier version of the sensor, all
study participants used an inhaler sensor mounted to the
end of the MDI canister by means of a small adapter cap
(Sensor Model I, Fig. 1) and were provided a mobile
smartphone to use for the study. Using a secure, low-power,
wireless radio protocol, the sensor transmitted collected
data to the paired mobile smartphone, which then com-
municated event information to the system servers. The
sensor contained a real-time clock and operating system
which time-stamped each separate actuation event when it
occurred. Industry standard encryption was used for all
exchanges of personal health information with the Propeller
Health application.
In this observational pilot study, participants were in-
structed to continue their COPD medications prescribed by
their caring provider as directed. The study staff did not
provide any specific instruction on how often or when to use
their albuterol MDI to capture the participants’ actual rather
than optimal usage pattern. If the participant used nebulized
medications such as albuterol or ipratropium, they were also
instructed to continue to use these medications as prescribed
by their medical care provider.
After completion of the study, participants were provided
a satisfaction questionnaire to evaluate their experience with
the sensor. Because of the differences in design between the
preliminary version of the inhaler sensor used by the initial
three subjects, results from the satisfaction questionnaire
included responses from those who used the more recent
Model 1 version.
COPD exacerbations
Each month participants were asked by phone if they de-
veloped symptoms of a COPD exacerbation during the past
4 weeks, including any details related to treatment and
FIG. 1. Inhaler sensor.















































healthcare use. COPD exacerbations were self-reported and
defined as an increase in, or new onset of, one or more re-
spiratory symptoms (cough, sputum, wheezing, dyspnea, or
chest tightness) lasting for two or more days. Exacerbations
were categorized as symptom only (mild), requiring the use
of prednisone and/or antibiotics (moderate) or requiring care
in the emergency department (ED) or hospitalization (severe).
To ensure that all participants began the study at their base-
line stable state, participants were required to wait at least 4
weeks after any COPD exacerbation before study enrollment.
Dates of ED visits and hospitalizations were confirmed in the
subject’s VA electronic medical record when available.
Analysis
Using daily self-reported exacerbation status (exacerba-
tion day vs. nonexacerbation day) as the unit of analysis, we
used generalized estimating equations with a logit link to
compare the odds of an exacerbation day compared to a
nonexacerbation day by the frequency of albuterol use.
Using log transformed puffs per day as the primary predictor
we calculated the average odds of an exacerbation day as-
sociated with a 25%, 50%, and 100% increase in albuterol
use. We considered the following potential confounders:
FEV1% predicted, supplemental oxygen use, exacerbation
within the previous year, concurrent inhaler therapy (long-
acting beta-agonist, long-acting anticholinergic, or inhaled
corticosteroid), gastroesophageal reflux disease,(12) and
dyspnea(11) (measured at baseline by the SOBQ).(9) FEV1%
predicted and inhaled corticosteroid use was associated with
inhaler use in bivariate analysis and was therefore included
in the final model.
To investigate whether the relationship between albuterol
use and the odds of an exacerbation differed by exacerbation
severity, we performed subgroup analyses to compare (1)
mild exacerbation days to nonexacerbation days and (2)
moderate-to-severe exacerbation days to nonexacerbation
days. In a sensitivity analysis, we repeated the models
comparing the odds of an exacerbation day to only the
nonexacerbation days preceding the first exacerbation.
The version of the inhaler sensor used in this study did not
allow us to differentiate between days when a participant did
not use their inhaler and days when the sensor was not
charged or was turned off. In 11 participants who returned a
daily diary, sensor data were missing 23% of the time during
days when participants recorded inhaler use in the diary.
Therefore, days with no sensor data were excluded since
imputing all missing days as 0 puffs would likely be inac-
curate.
Results
Characteristics of study participants
A total of 35 participants enrolled in the study (Fig. 2). One
participant died from complications of pneumonia, resulting
in 34 participants who completed the study. Mean age was 66
years, with an average of 68 pack-years smoking history.
Participants had moderate-to-severe airflow obstruction, with
a mean FEV1 of 1.4 – 0.1 liters among participants with ‡1
exacerbation and 1.8 – 0.4 among participants not reporting
an exacerbation (Table 1).
Characteristics of COPD exacerbations
The median number of days from the baseline period to
the first exacerbation was 18 days (interquartile range [IQR]:
7–31). There were 48 exacerbation events observed in 29
participants. The average number of exacerbations reported
was 1.4 – 0.9 events. The median length of an exacerbation
was 9.5 days (Table 2). Twelve participants reported a total of
FIG. 2. Participant flow diagram.















































16 moderate-to-severe exacerbations (median duration
14 days [IQR: 8.5–22.5]). The median days of prednisone
and/or antibiotic use was 9.5 (IQR: 7–17.5), and the median
hospitalization length was 3 days (IQR: 2.5–3.5).
Daily albuterol use measured with the inhaler sensor
The 35 participants had 3199 days of follow-up, and the
inhaler sensor recorded at least one puff per day for 69.1% of
days. An example of daily albuterol use recorded by the in-
haler sensor in one participant is shown in Figure 3 (a par-
ticipant hospitalized for an exacerbation). The average daily
albuterol use for each participant during nonexacerbation
days ranged from 1.5 to 17.3 puffs per day. The median of
average daily albuterol use during nonexacerbation days was
3.9 (IQR 2.7–6.3), but in 23% of the nonexacerbation days,
more than eight puffs a day of albuterol were used.
Change in albuterol use during exacerbation
There was a median increase in albuterol use of 5.9%
(IQR: -12.4% to 27.3%) comparing average mild exacer-
bation days to average nonexacerbation days (Fig. 4A) and a
median increase of 14.1% (IQR: 2.7%–56.9%) comparing
average moderate-to-severe exacerbation days to average
nonexacerbation days (Fig. 4B).
We next modeled the odds for an exacerbation associated with
the increase in number of puffs during any exacerbation day
Table 1. Baseline Characteristics and Average Daily Albuterol Use for Study Participants





N = 29 N = 6 p
Age years, mean (SD) 67.3 (1.4) 62.5 (4.6) 0.21
Male gender, % 93.1 100.0 0.51
>12th grade education, % 89.7 50.0 0.02
Smoking pack-years, mean (SD) 69.4 (6.2) 59.7 (16.4) 0.53
Dyspnea





SOBQ Scored, mean (SD) 51.2 (4.3) 56.0 (4.7) 0.63
Spirometry
FEV1, liters, mean (SD) 1.4 (0.1) 1.8 (0.4) 0.16
FEV1% predicted, mean (SD) 43.9 (3.1) 49.8 (8.2) 0.45
COPD GOLD Stage, %b 0.16
II: 50‡FEV1 > 80% 31.0 50.0
III: 30‡FEV1 > 50% 44.8 33.3
IV: FEV1 < 30% 24.1 16.7
Comorbidity
Coronary artery disease, % 31.0 33.3 0.91
Heart failure, % 10.3 0 0.41
Chronic heartburn, % 48.3 50.0 0.94
COPD-related healthcare use
ED visit in last year for COPD, % 37.9 50.0 0.58
Hospitalized in last year for COPD, % 27.6 16.7 0.58
COPD medications
Inhaled steroid use, % 58.6 66.7 0.71
Long-acting beta-agonist use, % 69.0 66.7 0.91
Long-acting anticholinergic use, % 51.7 50.0 0.94
Albuterol nebulizer use, % 44.8 50.0 0.82
Ipratropium nebulizer use, % 10.3 0.0 0.41
Supplemental oxygen use, % 51.7 33.3 0.41
Average daily albuterol use during the study
During stable breathing, median (IQR)c 3.8 (2.6–7.7) 3.8 (2.7–5.6) 0.86
During exacerbations, median (IQR)c 4.2 (2.5–8.6) NA
aParticipants with MMRC = 4 were excluded from the study.
bParticipants with FEV1 > 80% were excluded from the study.
cThe mean albuterol use (puffs) was calculated for each participant, then the median (IQR) of the means of participant albuterol was
calculated.
ED, emergency department; IQR, interquartile range; SD, standard deviation; MMRC, Modified Medical Research Council; COPD
GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV1, forced expiratory volume in 1 second; SOBQ, Shortness of Breath
Questionnaire.















































compared to nonexacerbation days in all 48 exacerbation events
(mild, moderate, or severe) among 29 participants. For an av-
erage participant, a 100% increase in daily albuterol puffs was
associated with an odds ratio (OR) of 1.24 (95% CI: 1.11–1.39)
for a COPD exacerbation. In other words, for a participant whose
albuterol use increased from four to eight puffs per day, the odds
of experiencing an exacerbation increased by 24% (95% CI:
11%–39%). Adjusting for FEV1% predicted and inhaled corti-
costeroid use did not appreciably change the estimate.
We then performed a subgroup analysis by severity of ex-
acerbation comparing: (1) mild exacerbation days (405 days) to
nonexacerbation days (1246 days) in 29 participants with mild
exacerbations and (2) moderate and severe exacerbation days
(222 days) to nonexacerbation days (1246 days) in 28 partici-
pants who had moderate-to-severe exacerbations. A 100% in-
crease in inhaler use was associated with an OR of 1.54 (95%
CI: 1.21–1.97) in a moderate-to-severe exacerbation adjusted
for FEV1% predicted and corticosteroid use (Table 3). We next
compared only those baseline days that preceded an exacer-
bation to all moderate and severe exacerbation days in a sen-
sitivity analysis and observed an increase in odds of an
exacerbation with a 100% increase in daily use of albuterol of
1.23 (95% CI: 1.07–1.44).
Satisfaction with the inhaler sensor
Overall, 74.1% of participants were very satisfied with the
inhaler sensor (Table 4). While most participants commented
that using the inhaler sensor did not affect their daily routine,
some participants noted that using the sensor on the albuterol
Table 2. Characteristics of Chronic Obstructive
Pulmonary Disease Exacerbations Observed




Length of exacerbation in days,
median (IQR)
9.5 (4–20)
Severity of exacerbation, n (%)






ED visit 3 (6.3)
FIG. 3. Example of a study participant’s daily albuterol use during nonexacerbation days and days of a reported severe
chronic obstructive pulmonary disease exacerbation.















































inhaler may have changed the way they used it. One partic-
ipant mentioned that he was more likely to question whether
he really needed the medication before using it. The sensor
gave feedback by blinking lights after actuation and when the
battery was low, but several participants expressed a need for
more feedback from the inhaler sensor to ensure that it was
working correctly.
Discussion
In this pilot study, we demonstrated that (1) a remote
inhaler sensor can monitor albuterol inhaler use in older
patients with COPD and is associated with high satisfaction,
(2) increased albuterol use captured by the sensor was as-
sociated with self-reported episodes of moderate-to-severe
exacerbations, yet (3) large variation was seen in the daily
use of albuterol in this population even in nonexacerbation
days. Prior studies have used this inhaler sensor to monitor
inhaler use for asthma patients(3); however, to our knowl-
edge, this is the first study reporting the use of inhaler
sensors in COPD patients during exacerbations.
Previous studies have evaluated the use of remote inhaler
sensors to assess adherence to controller medications. The
SmartTouch inhaler sensor improved the adherence to
inhaled steroids in adults and adolescents with asthma,(4,13)
and more recently, the use of the reminder function of the
inhaler sensor was shown to improve adherence and reduce
asthma morbidity in children who visited the ED for asthma
exacerbations.(5)
Another potential use of remote inhaler sensors is to assess
disease control. In asthma, monitoring SABA use is re-
commended as a measure of asthma control.(14) One small
study in which 30 patients with asthma used an inhaler sensor
to monitor short-acting bronchodilator use found that weekly
feedback to patients of inhaler use was associated with im-
provement in asthma control.(6) In a pragmatic randomized
controlled trial of 495 patients with asthma, use of the Pro-
peller Health sensor to monitor albuterol use was associated
with decreased albuterol use overall and improvement in
asthma control in the subgroup of adult patients who had
uncontrolled asthma at baseline.(7) However, the concept of
disease control in COPD is less developed,(15) and SABA use
as a measure of disease control in COPD is also not clear.
Since COPD exacerbations are often accompanied by
increased SABA use,(8) another potential use of real-time
monitoring of SABA inhaler use is early detection of COPD
exacerbations by the healthcare team to promptly initiate
appropriate therapy. Current telemonitoring approaches for
COPD include monitoring of symptoms or pulse oximetry;
however, results of telemonitoring in COPD have been
equivocal in terms of detection of exacerbations and re-
ducing healthcare utilization.(16)
FIG. 4. Average puffs during exacerbation and non-
exacerbation days among subjects with one or more exacer-
bation (N = 29). (a) Among subjects with one or more mild
exacerbation (N = 14), and (b) among subjects with one or
more moderate-to-severe exacerbation (N = 12). Each marker
represents an individual participant. An increase in average
daily albuterol use was observed for many of the participants
with moderate-to-severe exacerbations compared to non-
exacerbation days, but not for mild exacerbation days (me-
dian value for percent change in daily albuterol use was an
increase of 14.1% (IQR: 2.7%–56.9%) for participants with
moderate-to-severe exacerbations and 5.9% (IQR: -12.4% to
27.3%) in mild exacerbations). IQR, interquartile range.
Table 3. Odds of a Chronic Obstructive Pulmonary Disease Exacerbation Associated with Daily Changes
in Albuterol Reported by the Severity of Exacerbation
Associated ORexacerbation per x% increase in inhaler use
bLn(puffs) p 25% 50% 100%
Mild exacerbation days (n = 29; days = 1651)
Puffs per day 0.09 0.30 1.02 (0.98–1.06) 1.04 (0.97–1.11) 1.06 (0.95–1.19)
Adjusted puffs per daya 0.10 0.30 1.02 (0.98–1.07) 1.04 (0.96–1.12) 1.07 (0.94–1.22)
Moderate–severe exacerbation days (n = 28; days = 1468)
Puffs per day 0.65 <0.001 1.16 (1.07–1.25) 1.30 (1.13–1.50) 1.57 (1.23–1.99)
Adjusted puffs per daya 0.62 0.001 1.15 (1.06–1.24) 1.29 (1.12–1.48) 1.54 (1.21–1.97)
aModel adjusted for FEV1% predicted and concurrent inhaler corticosteroid use.
OR, odds ratio.















































Inhaler sensors may have advantages over existing tele-
monitoring methods as they can monitor inhaler use with
minimal effort by the patient without interrupting their usual
daily activity and, therefore, have potential for higher ad-
herence to the use of the monitoring device. A recent sys-
tematic analysis in the effectiveness of telemonitoring in
COPD patients in nine studies from 2011 to 2013 demon-
strated that telemonitoring may decrease overall healthcare
utilization,(17) and although patients were generally satisfied
with the devices they used, low adherence to these devices
was seen.(18)
In our study, we report the feasibility of using an inhaler
sensor to monitor SABA use in COPD patients. Most studies
using inhaler sensors focused on patients with asthma, who
tend to be younger and may be more comfortable with newer
technology. Participants in our study were older with a mean
age of 66 years, and many had comorbidities such as coronary
artery disease. In this group, we demonstrated that the inhaler
sensor was easy to use and that it captured increases in SABA
use associated with a moderate-to-severe exacerbation.
However, we also identified a potential challenge unique
to COPD patients. Unlike patients with asthma in whom
albuterol use is minimal during well-controlled days, in our
population albuterol use varied largely even during non-
exacerbation days indicating the difficulty in determining
the baseline use. In addition, some patients overused their
albuterol even in the nonexacerbation days.(19) Therefore,
our study suggests that future statistical models are likely
needed to account for individual baseline short-acting
bronchodilator use to more accurately detect the early de-
velopment of a COPD exacerbation.
Several limitations are important to note. Our study was a
3-month pilot study to assess the feasibility of inhaler sensor
usage in COPD, so the analysis of the association of COPD
exacerbation with changes in the number of albuterol puffs
was likely underpowered. In addition, we relied on self-report
to identify exacerbations, so inaccuracies may exist in re-
calling the exact start and end dates of the exacerbations, as
well as in recalling mild worsening of symptoms. Although
we observed COPD exacerbations in 83% of the participants
during the 3-month study period, most of these were mild and
only 12 (34%) had moderate-to-severe exacerbations.
In addition, the 3-month observation time may not have
been sufficient to establish a true baseline value especially
given the large fluctuations in rescue inhaler use even during
participants’ stable state. In addition, inhaler sensor data
were available for only 70% of follow-up days for each
participant. This is not unusual for an intervention in which
patient data are collected every day and consistent with a
study of pedometer use in COPD during which patients
wore their pedometer 77% of the time.(20) It is possible we
underestimated albuterol use if participants increased albu-
terol nebulizer use at home or received albuterol nebulizers
or MDIs in the ED or hospital which may have attenuated
the relationship between albuterol use and exacerbations.
For the 30% of time that sensor data were not available, we
were not able to determine whether this was due to no inhaler
use on a given day or whether the sensor battery was not
charged or was turned off. We observed that among the 11
participants in this study who also completed a daily diary,
sensor use data were missing an average of 23% of the time
during days with corresponding self-reported diary use sug-
gesting that most missing sensor days were due to the sensor
either not being charged or not being used with the inhaler.
The newest generation of this sensor automatically records
whether the sensor is operational, even during days in which
it is not used, so it can differentiate whether there is a tech-
nical issue with the sensor or the sensor is not used.
We provided smartphones to participants because we as-
sumed that many would not own their own. To ensure that
more COPD patients are able to use this type of inhaler
monitoring program, alternative ways to transmit data that do
not require a smartphone such as transmitting data automat-
ically through Bluetooth connection to a data hub at the pa-
tient’s home should be considered. These issues indicate that
regular follow-up and reminders on how to use the device, as
well as availability of technical support, are likely important
to successful electronic monitoring of inhaler use.
Conclusion
We found that a remote inhaler sensor was convenient for
most of these older participants with COPD over a 3-month
period in our pilot study. Increased albuterol use captured by
the sensor was associated with self-reported episodes of
moderate-to-severe exacerbations, but not in mild untreated
exacerbations. Further studies of longer duration are nec-
essary to establish a stable state of inhaler use patterns and
to capture multiple episodes of exacerbation to fully eval-
uate the device’s utility in early real-time identification of
exacerbations and prompt treatment.
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